Unveiling the unexpected: refractory rickets as an uncommon presentation of tyrosinemia type I. [PDF]
Ramanna MB, Kamate M, Koppad B.
europepmc +1 more source
Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria. [PDF]
Chandani HK +4 more
europepmc +1 more source
SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights. [PDF]
Saraceno E +8 more
europepmc +1 more source
Combined alkaptonuria and osteoporosis contributing to chronic back pain. [PDF]
Riegler A, Anand G.
europepmc +1 more source
Early-Onset Degenerative Bone Changes as a Manifestation of Alkaptonuria: A Case Report. [PDF]
Braga R, Teixeira F, Matos C.
europepmc +1 more source
In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Features of Corneal Pseudodendritic Lesions in Hereditary Tyrosinemia Type 1. [PDF]
Bruno R +3 more
europepmc +1 more source
Drug-induced cataract: a real-world study based on the food and drug administration adverse event reporting system database. [PDF]
Cao X +5 more
europepmc +1 more source
Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study. [PDF]
Antoni G +4 more
europepmc +1 more source
Alkaptonuria and Cervical Disc Herniation: Case Report. [PDF]
Sampaio Júnior FAU +11 more
europepmc +1 more source

